FIELD: biotechnology.
SUBSTANCE: invention refers to biotechnology, particularly to diagnosing infectious diseases. Method involves examining a specific set of biological material of patients, such as blood and respiratory tract samples: BAL, bronchial biopsy material and sputum. Detecting CMV DNA in a blood sample selected from whole blood in a concentration of not more than 1.0 lg copies in 105 leukocytes or blood plasma, as well as BAL sample – in concentration of not more than 400 copies/ml and/or bronchial biopsy material – not more than 400 copies/105 cells and/or sputum – not more than 3,500 copies/ml with 90 % probability excludes the presence of CMV-pneumonia and enables to conclude on the presence of lung involvement of other aetiology.
EFFECT: invention can be used for specification of aetiology of lung pathology in HIV-infected patients, particularly elimination or confirmation of pneumonia of cytomegalovirus nature (cytomegalovirus pneumonia, CMV-pneumonia).
1 cl, 2 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF AETIOLOGICAL VERIFICATION OF CYTOMEGALOVIRUS ENCEPHALITIS IN PATIENTS WITH HIV INFECTION | 2023 |
|
RU2812981C1 |
| METHOD FOR ASSESSMENT OF ACTIVITY OF INFECTION CAUSED BY HERPES TYPE 4, 5 AND 6 IN CHILDREN | 2016 |
|
RU2639593C1 |
| METHOD OF TREATING GENERALIZED CYTOMEGALOVIRUS INFECTION IN CHILDREN OF EARLY AGE | 2015 |
|
RU2602953C1 |
| METHOD FOR ASSESSING SEVERITY OF MENINGOENCEPHALITIS OF HERPETIC AETIOLOGY IN HIV INFECTION | 2017 |
|
RU2691710C2 |
| METHOD FOR DIAGNOSING DISSEMINATED PULMONARY TUBERCULOSIS IN PATIENTS WITH HIV INFECTION AND NEGATIVE RESULTS OF BACTERIOSCOPIC AND IMMUNOLOGICAL METHODS | 2020 |
|
RU2750525C1 |
| METHOD FOR PREDICTION OF LETHAL OUTCOME IN CLINICAL COURSE OF COINFECTION OF HIV AND TUBERCULOSIS, ACCOMPANIED BY MULTIPLE DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | 2019 |
|
RU2710266C1 |
| METHOD FOR PREDICTING THE SURVIVAL PERIOD OF PATIENTS WITH THE CLINICAL COURSE OF HIV AND TUBERCULOSIS COINFECTION, ACCOMPANIED BY MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | 2021 |
|
RU2764830C1 |
| METHOD FOR PREDICTING HUMAN TYPE 6 HERPES VIRUS INFECTION IN CHILDREN | 2018 |
|
RU2695323C1 |
| METHOD FOR DETECTING AND LABORATORY CONFIRMATION OF INHERITED CHROMOSOMALLY-INTEGRABLE HUMAN HERPES VIRUS 6A/B | 2020 |
|
RU2739997C1 |
| METHOD FOR DETERMINING THE GENETIC PREDISPOSITION TO THE DEVELOPMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS MYCOBACTERIUM TUBERCULOSIS IN HIV INFECTION | 2020 |
|
RU2750715C1 |
